

FOXO4-DRI Dosing Chart

An investigational 'senolytic' peptide designed to clear senescent (aged) cells. Studied in animals; no human trials. Commonly discussed doses: 5 mg–20 mg. No established dosing exists — FOXO4-DRI has only been studied in animals. Figures shown are reference points from research discussion in micrograms. There is no approved or established human dose.

thelastpeptide.com · Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC · Last reviewed 2026-08-02

FDA STATUS

Not FDA-approved for any use. FOXO4-DRI is a research peptide with no human trials and is not reviewed by FDA.

10 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	5 mg	10 mg	20 mg
1 mL	10	50 u	100 u	—
2 mL	5	100 u	—	—
3 mL	3.33	—	—	—

"—" means the draw exceeds one syringe at that concentration. Interactive calculator for any combination: thelastpeptide.com/peptides/foxo4-dri

FOXO4-DRI dose figures are commonly discussed reference information with no approved labeling unless stated above. The Last Peptide is an educational reference and sells nothing. Dosing figures shown here are commonly discussed reference information, not prescriptions or medical advice. Many peptides listed are not FDA-approved. Talk to a licensed clinician before using any peptide.